Table II.
Eligible studies in alphabetical order (n = 17)
| 1st author [ref.]# (year), country | CSD | DUR | RES | N | T-P and age | RES Group | Controls | BMI |
|---|---|---|---|---|---|---|---|---|
| Agarwal [67] (2013), USA | P | 30 | 400 | 41 | Healthy ≥ 18 |
N = 201 | N = 21 (PBO) | – |
| Bashmakov [47] (2014), Sweden |
P | 60 | 100 | 24 | T2DM 54.0 ±10.1 |
N = 14 (c) | N = 10 (PBO) | – |
| Brasnyo [68] (2011), Hungary |
P | 30 | 10 | 19 | T2DM 57.9 ±7.9 |
N = 10 (c) | N = 9 (PBO) | – |
| Chachay [69] (2014), Australia |
P | 56 | 3000 | 20 | Obese 48.8 ±12.2 |
N = 10 (c) | N = 10 (PBO) | 31.8 |
| Dash [70] (2013), Canada | C-O | 14 | 20002 | 16 | Obese 45.8 ±8.8 |
N = 8 (p2) | N = 8 (PBO) | 31.1 ±4.8 |
| Faghihzadeh [71] (2015), Iran |
P | 84 | 500 | 50 | NAFLD 44.4 ±10.1 |
N = 25 (c) | N = 25 (PBO) | 28.3 ±3.5 |
| Ghanim [72] (2010), USA | P | 42 | 40 | 20 | Healthy 36 ±5 |
N = 10 (c) | N = 10 (PBO) | 21.8 ±0.5 |
| Kumar [73] (2013), India | P | 182 | 250 | 57 | T2DM 57.7 ±8.9 |
N = 28 (c + OHAs) |
N = 29 (OHAs only) |
24.7 ±3.6 |
| Magyar [74] (2012), Hungary |
P | 90 | 10 | 40 | CAD (stable), 65.3 ±9.7 |
N = 20 (t) | N = 20 (PBO) | 29.3 ±2.1 |
| Mendez-del Villar [83] (2014), Mexico |
P | 90 | 1500 | 24 | Met-S 30–50 years |
N = 12 (c) | N = 12 (PBO) | – |
| Militaru [76] (2013), Romania |
P | 60 | 20 | 58 | CAD (stable), 64.9 ±5.8 |
N = 29 (c) | N = 29 (Nil) | – |
| Movahed [77] (2013), Iran | P | 45 | 1000 | 66 | T2DM 52.4 ±6.1 |
N = 33 (c) | N = 33 (PBO) | 27.1 ±3.1 |
| Poulsen [78] (2013), Denmark |
P | 28 | 500 | 24 | Obese 44.7 ±12.1 |
N = 12 (t) | N = 12 (PBO) | 32.5 ±2.1 |
| Timmers [79] (2011), Netherlands |
C-O | 30 | 150 | 22 | Obese 52.5 ±2.1 |
N = 11 (c) | N = 11 (PBO) | 31.5 ±2.7 |
| Tome-Carneiro [80] (2013), Spain (Cardiovasc Drugs Ther) |
P | 365 | 350 | 50 | CAD stable 60 ± 12 | N = 25 | N = 25 | 29.7 ±5.1 |
| Van der Made [81] (2015), Netherlands | C-O | 28 | 150 | 90 | Obese 60 ±7 | N = 45 (c) | N = 45 (PBO) | 28.3 ±3.2 |
| Yoshino [82] (2012), USA | P | 84 | 75 | 30 | Healthy 58.2 ±4.0 |
N = 15 (c) | N = 15 (PBO) | 24.2 ±2.8 |
Age (baseline and in years), CSD – clinical study design, DUR – duration (days), RES – resveratrol (mg/dl), N – number of subjects, P – parallel, C-O – cross-over, T-P – target-population, BMI – body-mass index (kg/m2), 1different formulation; 21 g/day for 1 week, then 2 g/day for 1 week, OHA – oral hypoglycaemic agents, PBO – placebo, c – capsules, p – pills, t – tablets. Faghihzadeh et al. presented data of all 50 subjects, but one patient (control group) discontinued the study because of disliking to continue and one patient (intervention group) may have been omitted from the final evaluation having body weight loss more than 10% of baseline.